Cargando…

The ischemic preconditioning effect of adenosine in patients with ischemic heart disease

INTRODUCTION: In vivo and in vitro evidence suggests that adenosine and its agonists play key roles in the process of ischemic preconditioning. The effects of low-dose adenosine infusion on ischemic preconditioning have not been thoroughly studied in humans. AIMS: We hypothesised that a low-dose ade...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadigh, Bita, Quintana, Miguel, Sylvén, Christer, Berglund, Margareta, Brodin, Lars Åke
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779183/
https://www.ncbi.nlm.nih.gov/pubmed/19891770
http://dx.doi.org/10.1186/1476-7120-7-52
_version_ 1782174345520480256
author Sadigh, Bita
Quintana, Miguel
Sylvén, Christer
Berglund, Margareta
Brodin, Lars Åke
author_facet Sadigh, Bita
Quintana, Miguel
Sylvén, Christer
Berglund, Margareta
Brodin, Lars Åke
author_sort Sadigh, Bita
collection PubMed
description INTRODUCTION: In vivo and in vitro evidence suggests that adenosine and its agonists play key roles in the process of ischemic preconditioning. The effects of low-dose adenosine infusion on ischemic preconditioning have not been thoroughly studied in humans. AIMS: We hypothesised that a low-dose adenosine infusion could reduce the ischemic burden evoked by physical exercise and improve the regional left ventricular (LV) systolic function. MATERIALS AND METHODS: We studied nine severely symptomatic male patients with severe coronary artery disease. Myocardial ischemia was induced by exercise on two separate occasions and quantified by Tissue Doppler Echocardiography. Prior to the exercise test, intravenous low-dose adenosine or placebo was infused over ten minutes according to a randomized, double blind, cross-over protocol. The LV walls were defined as ischemic if a reduction, no increment, or an increment of < 15% in peak systolic velocity (PSV) was observed during maximal exercise compared to the baseline values observed prior to placebo-infusion. Otherwise, the LV walls were defined as non-ischemic. RESULTS: PSV increased from baseline to maximal exercise in non-ischemic walls both during placebo (P = 0.0001) and low-dose adenosine infusion (P = 0.0009). However, in the ischemic walls, PSV increased only during low-dose adenosine infusion (P = 0.001), while no changes in PSV occurred during placebo infusion (P = NS). CONCLUSION: Low-dose adenosine infusion reduced the ischemic burden and improved LV regional systolic function in the ischemic walls of patients with exercise-induced myocardial ischemia, confirming that adenosine is a potential preconditioning agent in humans.
format Text
id pubmed-2779183
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27791832009-11-19 The ischemic preconditioning effect of adenosine in patients with ischemic heart disease Sadigh, Bita Quintana, Miguel Sylvén, Christer Berglund, Margareta Brodin, Lars Åke Cardiovasc Ultrasound Research INTRODUCTION: In vivo and in vitro evidence suggests that adenosine and its agonists play key roles in the process of ischemic preconditioning. The effects of low-dose adenosine infusion on ischemic preconditioning have not been thoroughly studied in humans. AIMS: We hypothesised that a low-dose adenosine infusion could reduce the ischemic burden evoked by physical exercise and improve the regional left ventricular (LV) systolic function. MATERIALS AND METHODS: We studied nine severely symptomatic male patients with severe coronary artery disease. Myocardial ischemia was induced by exercise on two separate occasions and quantified by Tissue Doppler Echocardiography. Prior to the exercise test, intravenous low-dose adenosine or placebo was infused over ten minutes according to a randomized, double blind, cross-over protocol. The LV walls were defined as ischemic if a reduction, no increment, or an increment of < 15% in peak systolic velocity (PSV) was observed during maximal exercise compared to the baseline values observed prior to placebo-infusion. Otherwise, the LV walls were defined as non-ischemic. RESULTS: PSV increased from baseline to maximal exercise in non-ischemic walls both during placebo (P = 0.0001) and low-dose adenosine infusion (P = 0.0009). However, in the ischemic walls, PSV increased only during low-dose adenosine infusion (P = 0.001), while no changes in PSV occurred during placebo infusion (P = NS). CONCLUSION: Low-dose adenosine infusion reduced the ischemic burden and improved LV regional systolic function in the ischemic walls of patients with exercise-induced myocardial ischemia, confirming that adenosine is a potential preconditioning agent in humans. BioMed Central 2009-11-05 /pmc/articles/PMC2779183/ /pubmed/19891770 http://dx.doi.org/10.1186/1476-7120-7-52 Text en Copyright ©2009 Sadigh et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Sadigh, Bita
Quintana, Miguel
Sylvén, Christer
Berglund, Margareta
Brodin, Lars Åke
The ischemic preconditioning effect of adenosine in patients with ischemic heart disease
title The ischemic preconditioning effect of adenosine in patients with ischemic heart disease
title_full The ischemic preconditioning effect of adenosine in patients with ischemic heart disease
title_fullStr The ischemic preconditioning effect of adenosine in patients with ischemic heart disease
title_full_unstemmed The ischemic preconditioning effect of adenosine in patients with ischemic heart disease
title_short The ischemic preconditioning effect of adenosine in patients with ischemic heart disease
title_sort ischemic preconditioning effect of adenosine in patients with ischemic heart disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779183/
https://www.ncbi.nlm.nih.gov/pubmed/19891770
http://dx.doi.org/10.1186/1476-7120-7-52
work_keys_str_mv AT sadighbita theischemicpreconditioningeffectofadenosineinpatientswithischemicheartdisease
AT quintanamiguel theischemicpreconditioningeffectofadenosineinpatientswithischemicheartdisease
AT sylvenchrister theischemicpreconditioningeffectofadenosineinpatientswithischemicheartdisease
AT berglundmargareta theischemicpreconditioningeffectofadenosineinpatientswithischemicheartdisease
AT brodinlarsake theischemicpreconditioningeffectofadenosineinpatientswithischemicheartdisease
AT sadighbita ischemicpreconditioningeffectofadenosineinpatientswithischemicheartdisease
AT quintanamiguel ischemicpreconditioningeffectofadenosineinpatientswithischemicheartdisease
AT sylvenchrister ischemicpreconditioningeffectofadenosineinpatientswithischemicheartdisease
AT berglundmargareta ischemicpreconditioningeffectofadenosineinpatientswithischemicheartdisease
AT brodinlarsake ischemicpreconditioningeffectofadenosineinpatientswithischemicheartdisease